Peter Alping

Validation of the Swedish Multiple Sclerosis registry for pediatric-onset multiple sclerosis

• Multiple Sclerosis Journal – Experimental, Translational and Clinical
• DOI: 10.1177/20552173251314118

Fredrik Sandesjö, Peter Alping, Katharina Fink, Ronny Wickström, Fredrik Piehl, Thomas Frisell, and Kyla A McKay

Creative Commons Attribution 4.0 International License (CC-BY)

Hospital-Treated Infections and Risk of Disability Worsening in Multiple Sclerosis

• Annals of Neurology
• DOI: 10.1002/ana.27026

Yihan Hu, Thomas Frisell, Peter Alping, Huan Song, Yudi Pawitan, Fang Fang, and Fredrik Piehl

Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC-BY-NC-ND)

Real-World Healthcare Cost Savings and Reduced Relapse Rate with Off-Label Rituximab versus Disease-Modifying Treatments Approved for Relapsing–Remitting Multiple Sclerosis: A Nationwide Cost-Effectiveness Study

• Annals of Neurology
• DOI: 10.1002/ana.26914

Peter Alping, Martin Neovius, Fredrik Piehl, and Thomas Frisell

Creative Commons Attribution-NonCommercial 4.0 International License (CC-BY-NC)

Disease-modifying therapies in multiple sclerosis: A focused review of rituximab

• Basic & Clinical Pharmacology & Toxicology
• DOI: 10.1111/bcpt.13932

Peter Alping

Creative Commons Attribution-NonCommercial 4.0 International License (CC-BY-NC)

Multiple sclerosis, disease-modifying drugs and risk for adverse perinatal and pregnancy outcomes: Results from a population-based cohort study

• Multiple Sclerosis
• DOI: 10.1177/13524585231161492

Katharina Fink, Agnes Gorczyca, Peter Alping, Simon Englund, Susan Farmand, Annette M. Langer-Gould, Fredrik Piehl, Kyla McKay, Thomas Frisell, and Neda Razaz

Creative Commons Attribution 4.0 International License (CC-BY)

Pharmacoepidemiological Studies of Rituximab and Other Recent Therapies in Multiple Sclerosis

• Thesis
• Karolinska Institutet
• Sweden

Peter Alping

Creative Commons Attribution 4.0 International License (CC-BY)

Safety of Alemtuzumab and Autologous Hematopoietic Stem Cell Transplantation Compared to Noninduction Therapies for Multiple Sclerosis

• Neurology
• DOI: 10.1212/WNL.0000000000011545

Peter Alping, Joachim Burman, Jan Lycke, Thomas Frisell, and Fredrik Piehl

Creative Commons Attribution 4.0 International License (CC-BY)

Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies

• JAMA Neurology
• DOI: 10.1001/jamaneurol.2019.3365

Gustavo Luna, Peter Alping, Joachim Burman, Katharina Fink, Anna Fogdell-Hahn, Martin Gunnarsson, Jan Hillert, Annette Langer-Gould, Jan Lycke, Petra Nilsson, Jonatan Salzer, Anders Svenningsson, Magnus Vrethem, Tomas Olsson, Fredrik Piehl, and Thomas Frisell

Copyright 2019 American Medical Association. All Rights Reserved.

Validation of the Swedish Multiple Sclerosis Register: Further Improving a Resource for Pharmacoepidemiologic Evaluations

• Epidemiology
• DOI: 10.1097/ede.0000000000000948

Peter Alping, Fredrik Piehl, Annette Langer-Gould, Thomas Frisell, and COMBAT-MS Study Group

Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC-BY-NC-ND)

Rituximab in multiple sclerosis: A retrospective observational study on safety and efficacy

• Neurology
• DOI: 10.1212/wnl.0000000000003331

Jonatan Salzer, Rasmus Svenningsson, Peter Alping, Lenka Novakova, Anna Björck, Katharina Fink, Protik Islam-Jakobsson, Clas Malmeström, Markus Axelsson, Mattias Vågberg, Peter Sundström, Jan Lycke, Fredrik Piehl, and Anders Svenningsson

Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC-BY-NC-ND)

Rituximab versus Fingolimod after Natalizumab in Multiple Sclerosis Patients

• Annals of Neurology
• DOI: 10.1002/ana.24651

Peter Alping, Thomas Frisell, Lenka Novakova, Protik Islam-Jakobsson, Jonatan Salzer, Anna Björck, Markus Axelsson, Clas Malmeström, Katharina Fink, Jan Lycke, Anders Svenningsson, and Fredrik Piehl

Creative Commons Attribution-NonCommercial 4.0 International License (CC-BY-NC)